Study to evaluate the role of Pirfenidone in preventing radiation induced lung damage
- Conditions
- Health Condition 1: C348- Malignant neoplasm of overlappingsites of bronchus and lung
- Registration Number
- CTRI/2021/07/035223
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion criteria
1. 18-70 years old, male or female
2. General condition assessment, ECOG score of 0-1
3. Pathological diagnosis of lung cancer, with non-small cell lung cancer (NSCLC) staging IIIA or IIIB, and small cell lung cancer (SCLC)
4. Candidate for radical treatment with radiation therapy with or without chemotherapy
5. Expected survival at 6 months or more
Exclusion criteria
1. Unable to perform or any contra-indications for performing PFT
2. Concurrent / active pulmonary infection
3. Associated with other serious diseases: such as occurred within 6 months of myocardial infarction, uncontrolled diabetes etc.
4. Chronic liver disease/cirrhosis
5. With active peptic ulcer
6. Unwilling to take radiation therapy at TMH
7. Pregnant women and patients with known psychiatric/psychological disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method